Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 983-1002 , October 2006

Understanding the role of tissue degrading enzymes and their inhibitors in development and disease

  • Tim E. Cawston

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 191 222 5363; Fax: +44 191 222 5455.

References 

  1. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis and Rheumatism. 2000;43(9):1916–1926
  2. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annual Review of Biochemistry. 1998;67:609–652
  3. Mort JS, Billington CJ. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Research. 2001;3(6):337–341
  4. Barrett AJ, Rawlings ND, Woessner JF. Handbook of Proteolytic Enzymes. London: Academic Press; 1998;
  5. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Current Topics in Developmental Biology. 2003;54:101–123
  6. Everts V, Delaisse JM, Korper W, et al. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. Journal of Cellular Physiology. 1992;150(2):221–231
  7. Stocker W, Grams F, Baumann U, et al. The metzincins – topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Science: a Publication of the Protein Society. 1995;4(5):823–840
  8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer. 2002;2(3):161–174
  9. Boldt HB, Overgaard MT, Laursen LS, et al. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. The Biochemical Journal. 2001;358(2):359–367
  10. Overgaard MT, Boldt HB, Laursen LS, et al. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. The Journal of Biological Chemistry. 2001;276(24):21849–21853
  11. Nagase H, Woessner JF. Matrix metalloproteinases. The Journal of Biological Chemistry. 1999;274(31):21491–21494
  12. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation. Proceedings of the National Academy of Sciences of the USA. 1990;87:364–368
  13. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology. 2001;17:463–516
  14. Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opinion on Therapeutic Targets. 2003;7(1):19–34
  15. van den Berg WB. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. The Journal of Rheumatology. 1999;58(3):136–141
  16. Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Annals of the Rheumatic Diseases. 2002;61(8):704–713
  17. Cawston TE, Curry VA, Summers CA, et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localisation within the rheumatoid joint. Arthritis and Rheumatism. 1998;41(10):1760–1771
  18. Kleiner DE, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Current Opinion in Cell Biology. 1993;5(5):891–897
  19. Milner JM, Elliott SF, Cawston TE. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis and Rheumatism. 2001;44(9):2084–2096
  20. Milner JM, Rowan AD, Elliott SF, Cawston TE. Inhibition of furin-like enzymes blocks interleukin-1alpha/oncostatin M stimulated cartilage degradation. Arthritis and Rheumatism. 2003;48(4):1057–1066
  21. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61–65
  22. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library – MT-MMPs form a unique membrane-type subclass in the MMP family. The Journal of Biological Chemistry. 1995;270:23013–23020
  23. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. European Journal of Biochemistry. 1997;244(2):653–657
  24. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. The Journal of Biological Chemistry. 1999;274(13):8925–8932
  25. Velasco G, Cal S, Merlos-Suárez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation and expression in brain tumors. Cancer Research. 2000;60(4):877–882
  26. Cawston TE. Metalloproteinases inhibitors and the prevention of connective tissue breakdown. Pharmacology and Therapeutics. 1996;70(3):163–182
  27. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta. 2000;1477(1–2):267–283
  28. Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. The Journal of Biological Chemistry. 1996;271:30375–30380
  29. Varga J, Rosenbloom J, Jimenez A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. The Biochemical Journal. 1987;247(3):597–604
  30. Tchetverikov I, Verzijl N, Huizinga TW, et al. Active MMPs captured by alpha 2 macroglobulin as a marker of disease activity in rheumatoid arthritis. Clinical and Experimental Rheumatology. 2003;21(6):711–718
  31. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Current Topics in Developmental Biology. 2003;54:1–74
  32. Yu WH, Woessner JF. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). The Journal of Biological Chemistry. 2000;275(6):4183–4191
  33. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Research. 2000;60(4):888–891
  34. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends in Genetics. 2000;16(2):83–87
  35. Campbell IK, Wojta J, Novak U, Hamilton JA. Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor a and up-regulation by transforming growth factor-b and basic fibroblast growth factor. Biochimica et Biophysica Acta. 1994;1226:277–285
  36. Bryson H, Bunning RAD, Feltell R, et al. A serine proteinase inactivator inhibits chondrocyte-mediated cartilage proteoglycan breakdown occurring in response to proinflammatory cytokines. Archives of Biochemistry and Biophysics. 1998;355(1):15–25
  37. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. The EMBO Journal. 2001;20(17):4629–4633
  38. Buttle DJ, Bramwell H, Hollander AP. Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?. Clinical Molecular Pathology. 1995;48:M167–M177
  39. Everts V, Van der Zee E, Creemers L, Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. The Histochemical Journal. 1996;28:229–245
  40. Inaoka T, Bilbe G, Ishibashi O, et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochemical and Biophysical Research Communications. 1995;206(1):89–96
  41. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. The Journal of Biological Chemistry. 1996;271(21):12517–12524
  42. Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. The Biochemical Journal. 1998;331(Pt 3):727–732
  43. Hummel KM, Petrow PK, Franz JK, et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. The Journal of Rheumatology. 1998;25(10):1887–1894
  44. Hou WS, Li W, Keyszer G, et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis and Rheumatism. 2002;46(3):663–674
  45. Li Z, Hou WS, Bromme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry. 2000;39(3):529–536
  46. Hou WS, Li Z, Gordon RE, et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. American Journal of Pathology. 2001;159(6):2167–2177
  47. Suzuki K, Shimizu K, Hamamoto T, et al. Characterization of proteoglycan degradation by calpain. The Biochemical Journal. 1992;285(Pt 3):857–862
  48. Szomor Z, Shimizu K, Fujimori Y, et al. Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. Annals of the Rheumatic Diseases. 1995;54(6):477–483
  49. Ishikawa H, Nakagawa Y, Shimizu K, et al. Inflammatory cytokines induced down-regulation of m-calpain mRNA expression in fibroblastic synoviocytes from patients with osteoarthritis and rheumatoid arthritis. Biochemical and Biophysical Research Communications. 1999;266(2):341–346
  50. Wlodawer A. Proteasome: a complex protease with a new fold and a distinct mechanism. Structure (London, England: 1993). 1995;3(5):417–420
  51. Ballock RT, O'Keefe RJ. Physiology and pathophysiology of the growth plate. Birth Defects Research. Part C, Embryo Today: Reviews. 2003;69(Part C):123–143
  52. Ornitz DM, Marie PJ. Fgf signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes and Development. 2002;16(12):1446–1465
  53. Provot S, Schipani E. Molecular mechanisms of endochondral bone development. Biochemical and Biophysical Research Communications. 2005;328(3):658–665
  54. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. Journal of Cell Science. 2000;113(Pt 3):377–381
  55. Stickens D, Behonick DJ, Ortega N, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development. 2004;131(23):5883–5895
  56. Olsen BR, Reginato AM, Wang W. Bone development. Annual Review of Cell and Developmental Biology. 2000;16:191–220
  57. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93(3):411–422
  58. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology. 2000;2(10):737–744
  59. Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. The Journal of Cell Biology. 2000;151(4):879–889
  60. Kennedy AM, Inada M, Krane SM, et al. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (Semdmo). The Journal of Clinical Investigation. 2005;115(10):2832–2842
  61. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proceedings of the National Academy of Sciences of the USA. 2000;97(8):4052–4057
  62. Ortega N, Behonick D, Stickens D, Werb Z. How proteases regulate bone morphogenesis. Annals of the New York Academy of Sciences. 2003;995:109–116
  63. Satoyoshi M, Kawata A, Koizumi T, et al. Matrix metalloproteinase-2 in dentin matrix mineralization. Journal of Endodontics. 2001;27(7):462–466
  64. Itoh T, Matsuda H, Tanioka M, et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. Journal of Immunology. 2002;169(5):2643–2647
  65. Choi SJ, Han JH, Roodman GD. ADAM8: a novel osteoclast stimulating factor. Journal of Bone and Mineral Research. 2001;16(5):814–822
  66. Verrier S, Hogan A, McKie N, Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone. 2004;35(1):34–46
  67. Dallas DJ, Genever PG, Patton AJ, et al. Localization of Adam10 and Notch receptors in bone. Bone. 1999;25(1):9–15
  68. Bartholin L, Destaing O, Forissier S, et al. FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation. Biology of the cell. 2005;97(7):577–588
  69. Shindo T, Kurihara H, Kuno K, et al. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. The Journal of Clinical Investigation. 2000;105(10):1345–1352
  70. Colige A, Li SW, Sieron AL, et al. cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proceedings of the National Academy of Sciences of the USA. 1997;94(6):2374–2379
  71. Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. The Journal of Biological Chemistry. 1999;274(36):25555–25563
  72. Tortorella MD, Burn TC, Pratta MA, Abbaszade I. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999;284(5420):1664–1666
  73. Matthews RT, Gary SC, Zerillo C, et al. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. The Journal of Biological Chemistry. 2000;275(30):22695–22703
  74. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005;434(7033):648–652
  75. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis and Rheumatism. 2001;44(3):585–594
  76. Shingleton WD, Ellis AJ, Rowan AD, Cawston TE. Retinoic acid combines with interleukin-1 to promote the degradation of collagen from bovine nasal cartilage: matrix metalloproteinases-1 and -13 are involved in cartilage collagen breakdown. Journal of Cellular Biochemistry. 2000;79(4):519–531
  77. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Annals of the Rheumatic Diseases. 1995;54:25–32
  78. Okada Y, Shinmei M, Tanaka O, et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Laboratory Investigation. 1992;66:680–690
  79. Wolfe GC, MacNaul KL, Buechel FF, et al. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage: quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis and Rheumatism. 1993;36:1540–1547
  80. Ahrens D, Koch AE, Pope RM, et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis and Rheumatism. 1996;39(9):1576–1587
  81. Gruber BL, Sorbi D, French DL, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potential useful laboratory marker. Clinical Immunology and Immunopathology. 1996;78(2):161–171
  82. Yoshihara Y, Nakamura H, Obata K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Annals of the Rheumatic Diseases. 2000;59:455–461
  83. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Annals of the Rheumatic Diseases. 1999;58(11):691–697
  84. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond. The Journal of Clinical Investigation. 1992;89(5):1512–1516
  85. Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biology. 2000;19:333–344
  86. Arner EC, Hughes CE, Decicco CP, et al. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis and Cartilage. 1998;6(3):214–228
  87. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. The Biochemical Journal. 2005;386(Pt 1):15–27
  88. Rodriguez-Manzaneque JC, Westling J, Thai SN, et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochemical and Biophysical Research Communications. 2002;293(1):501–508
  89. Collins-Racie LA, Flannery CR, Zeng W, et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biology. 2004;23(4):219–230
  90. Billington CJ, Clark IM, Cawston TE. An aggrecan-degrading activity associated with chondrocyte membranes. The Biochemical Journal. 1998;15(336 Pt 1):207–212
  91. Somerville RP, Longpre JM, Jungers KA, et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. The Journal of Biological Chemistry. 2003;278(11):9503–9513
  92. Stanton H, Ung L, Fosang AJ. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. The Biochemical Journal. 2002;364(Pt 1):181–190
  93. Dudler J, Renggli-Zulliger N, Busso N, Lotz M. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Annals of the Rheumatic Diseases. 2000;59(7):529–532
  94. Yamanishi Y, Boyle DL, Clark M, et al. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. Journal of Immunology (Baltimore, Md.: 1950). 2002;168(3):1405–1412
  95. Koshy PJ, Lundy CJ, Rowan AD, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis and Rheumatism. 2002;46(4):961–967
  96. Ellis AJ, Curry VA, Powell EK, Cawston TE. The prevention of collagen breakdown in bovine nasal cartilage by TIMP-1, TIMP-2 and a low molecular weight synthetic inhibitor. Biochemical and Biophysical Research Communications. 1994;201:94–101
  97. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). The Journal of Biological Chemistry. 2001;276(16):12501–12504
  98. Chevrier A, Mort JS, Crine P, et al. Soluble recombinant neprilysin induces aggrecanase-mediated cleavage of aggrecan in cartilage explant cultures. Archives of Biochemistry and Biophysics. 2001;396(2):178–186
  99. McKie N, Edwards T, Dallas DJ, et al. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochemical and Biophysical Research Communications. 1997;230(2):335–339
  100. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature. 1997;385:729–733
  101. Ronday HK, van der Laan WH, Tak PP, et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology. 2001;40(1):55–61
  102. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Annals of the New York Academy of Sciences. 1999;30(878):228–235
  103. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular Research. 2006;69:677–687
  104. Sabatini M, Lesur C, Thomas M, et al. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis and Rheumatism. 2005;52(1):171–180
  105. Ishikawa T, Nishigaki F, Miyata S, et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. European Journal of Pharmacology. 2005;508(1–3):239–247
  106. Ishikawa T, Nishigaki F, Miyata S, et al. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. British Journal of Pharmacology. 2005;144(1):133–143
  107. Lewis EJ, Bishop J, Bottomley KM, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. British Journal of Pharmacology. 1997;121(3):540–546
  108. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. Journal of Medicinal Chemistry. 1997;40(16):2525–2532
  109. O'Byrne EM, Blancuzzi V, Singh H, et al. Chondroprotective Activity of a Matrix Metalloproteinase Inhibitor, CGS 27023A in Animal Models of Osteoarthritis. Tokyo, Japan: Springer-Verlag; 1999;
  110. Chau T, Jolly G, Plym MJ, et al. Inhibition of articular cartilage degradation in dog and guinea-pig models of osteoarthritis by the stromelysin inhibitor, BAY-12–9566. Arthritis and Rheumatism. 1998;41:S300
  111. Levitt NC, Eskens FA, O'Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer. Clinical Cancer Research. 2001;7(7):1912–1922
  112. Hemmings FJ, Farhan M, Rowland J, et al. Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford, England). 2001;40(5):537–543
  113. Leff RL, Elias I, Ionescu M, et al. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. The Journal of Rheumatology. 2003;30(3):544–549
  114. Bayer drug casts shadow over MMP inhibitors in cancer. Scrip. 1999;2476:7
  115. Ryan ME, Greenwald RA, Golub LM. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Current Opinion in Rheumatology. 1996;8(3):238–247
  116. de Bri E, Lei W, Svensson O, et al. Effect of an inhibitor of matrix metalloproteinases on spontaneous osteoarthritis in guinea pigs. Advances in Dental Research. 1998;12(2):82–85
  117. Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. The Journal of Rheumatology. 2003;30(10):2112–2122
  118. van der Laan W, Molenaar E, Ronday K, et al. Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial. The Journal of Rheumatology. 2001;28(9):1967–1974
  119. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomised, placebo-controlled, double-blind trial. Arthritis and Rheumatism. 2005;52(7):2015–2025
  120. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer and Metastasis Reviews. 2003;22(2–3):177–203
  121. Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Current Opinion in Rheumatology. 2004;16(3):231–237
  122. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. The Journal of Clinical Investigation. 2001;108(1):73–81
  123. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappa B kinase beta is a key regulator of synovial inflammation. Arthritis and Rheumatism. 2001;44(8):1897–1907
  124. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. The Journal of Clinical Investigation. 2001;108(12):1781–1788
  125. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. The EMBO Journal. 2000;19(6):1176–1179
  126. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews. Drug Discovery. 2002;1(4):287–299
  127. Young DA, Lakey RL, Pennington CJ, et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Research and Therapy. 2005;7(3):R503–R512
  128. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discovery Today. 2005;10(3):197–204
  129. Nagase H, Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochemical Society Sympopsia. 2003;(70):201–212
  130. Lee MH, Rapti M, Knauper V, Murphy G. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. The Journal of Biological Chemistry. 2004;279(17):17562–17569
  131. Lee MH, Rapti M, Murphy G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of TNF-a converting enzyme (TACE). The Journal of Biological Chemistry. 2005;280(16):15967–15975
  132. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy. 2003;10(3):234–242

PII: S1521-6942(06)00075-1

doi: 10.1016/j.berh.2006.06.007

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 983-1002 , October 2006

Article Tools

* Image Usage & Resolution